Company Filing History:
Years Active: 2022-2025
Title: Joseph Custodio: Innovator in Cancer Treatment and ALS Research
Introduction
Joseph Custodio is a notable inventor based in Menlo Park, CA, who has made significant contributions to the fields of cancer treatment and amyotrophic lateral sclerosis (ALS) research. With a total of 4 patents to his name, Custodio's work focuses on innovative methods that enhance patient care and treatment outcomes.
Latest Patents
Custodio's latest patents include a method for normalizing the neutrophil to lymphocyte ratio in cancer patients using a selective glucocorticoid receptor antagonist. This method involves administering a nonsteroidal glucocorticoid receptor antagonist to cancer patients with a neutrophil-to-lymphocyte ratio greater than 3, effectively reducing their NLR and enhancing cancer treatment. The treatment may include chemotherapy, immunotherapy, and other modalities, ultimately improving patient prognosis and survival rates.
Another significant patent addresses treatments for ALS using dazucorilant, a heteroaryl ketone fused azadecalin compound. This patent outlines methods for administering dazucorilant to ALS patients, with suitable doses that can be taken daily. The pharmaceutical compositions developed for this treatment are designed for oral and enteral administration, providing new hope for those suffering from this debilitating condition.
Career Highlights
Joseph Custodio is currently associated with Corcept Therapeutics Incorporated, where he continues to innovate and develop new therapeutic methods. His work has garnered attention for its potential to improve the quality of life for patients facing serious health challenges.
Collaborations
Custodio collaborates with esteemed colleagues such as Hazel Joan Hunt and Grace Mann, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Joseph Custodio's contributions to medical research, particularly in cancer treatment and ALS, highlight his commitment to improving patient outcomes through innovative solutions. His patents reflect a dedication to advancing healthcare and providing new avenues for treatment.